KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells $39,875.42 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,489 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the transaction, the chief financial officer directly owned 21,661 shares of the company’s stock, valued at $580,081.58. This represents a 6.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Piekos also recently made the following trade(s):

• On Friday, April 17th, Brian Piekos sold 1,862 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ:KALV traded up $0.02 during trading on Tuesday, reaching $26.81. 8,068,030 shares of the stock traded hands, compared to its average volume of 7,414,539. The stock has a 50-day moving average of $21.74 and a two-hundred day moving average of $17.54. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The stock has a market cap of $1.43 billion, a P/E ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $39.17 million for the quarter, compared to the consensus estimate of $39.03 million. As a group, sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after acquiring an additional 88,720 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at $24,360,000. State Street Corp increased its holdings in KalVista Pharmaceuticals by 21.3% in the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock valued at $30,874,000 after acquiring an additional 336,195 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of KalVista Pharmaceuticals by 152.0% in the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after buying an additional 1,140,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its holdings in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after buying an additional 1,055,940 shares during the last quarter.

Wall Street Analyst Weigh In

KALV has been the topic of several analyst reports. Citizens Jmp cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. HC Wainwright cut shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $37.00 to $27.00 in a research note on Friday, May 1st. JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Stifel Nicolaus lifted their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Finally, Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.